title: Factor VII hyperactivity in chronic dialysis patients.
abstract: To study factor VII (F VII) hyperactivity in chronic dialysis patients, we measured the plasma levels of F VII activity (F VII c) and antigen (F VII Ag), prothrombin activation fragments 1 + 2 (F1 + 2), thrombin-antithrombin III complexes (TAT), and thrombomodulin in 28 patients on hemodialysis. Marked elevation of F VII c was found in long-term dialysis patients (185 +/- 30%). This hyperactivity was accompanied by both elevation of the F VII Ag level (153 +/- 28%) and enhanced activation of F VII zymogen, expressed as the F VII c/F VII Ag ratio (1.23 +/- 0.23), but pseudocholinesterase activity was decreased. The 6 patients with ischemic heart disease had slightly higher F VII c (200 +/- 25%) than those without ischemic heart disease (181 +/- 30%), although the difference was not significant. Increased F VII c was accompanied by factor Xa hyperactivity (a high plasma F1 + 2 level) in the long-term dialysis patients, but there was no significant elevation of plasma TAT levels when compared with controls matched for age, sex, and the presence or absence of diabetes mellitus. Plasma TAT levels were significantly correlated with plasma thrombomodulin levels, suggesting that thrombin generation in blood as a result of hemodialysis could induce systemic endothelial cell injury.
authors.affiliation: Department of Internal Medicine, Hyogo Prefectural Awaji Hospital, Sumoto, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Kario
authors.forename: T
authors.initials: T
authors.lastname: Matsuo
authors.forename: T
authors.initials: T
authors.lastname: Yamada
authors.forename: K
authors.initials: K
authors.lastname: Nakao
authors.forename: C
authors.initials: C
authors.lastname: Shimano
authors.forename: M
authors.initials: M
authors.lastname: Matsuo
mesh_terms: D000368:Aged; D000990:Antithrombin III / Q000032:analysis; D001780:Blood Coagulation Tests; D002091:Butyrylcholinesterase / Q000032:analysis; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000097:blood; D005167:Factor VII / Q000032:analysis*; D015942:Factor VIIa / Q000032:analysis*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood / Q000150:complications; D010446:Peptide Fragments / Q000032:analysis; D010447:Peptide Hydrolases / Q000032:analysis; D011516:Prothrombin / Q000032:analysis; D011956:Receptors, Cell Surface / Q000032:analysis; D018179:Receptors, Thrombin; D006435:Renal Dialysis; D014511:Uremia / Q000097:blood / Q000150:complications
chemical_list: D010446:Peptide Fragments; D011956:Receptors, Cell Surface; D018179:Receptors, Thrombin; C046193:antithrombin III-protease complex; C045879:prothrombin fragment 1.2; D000990:Antithrombin III; D005167:Factor VII; D011516:Prothrombin; D002091:Butyrylcholinesterase; D010447:Peptide Hydrolases; D015942:Factor VIIa